Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
A French biotech company has announced an agreement with a center for biomedical research of which it is a spin-off. 2 July 2019
Biotechnology
Nicox has entered into an exclusive license agreement with China’s Ocumension Therapeutics for the development and commercialization of Nicox’ product candidate, NCX 4251. 2 July 2019
Biotechnology
Israel’s leading drugmaker Teva Pharmaceutical has presented data from exploratory endpoints from the Phase IIIb FOCUS trial of Ajovy (fremanezumab), at the annual congress of the European Academy of Neurology (EAN). 2 July 2019
Biotechnology
National Health Service patients in the UK will be the first to gain access in Europe to new skin cancer treatment, Libtayo (cemiplimab), through the Cancer Drugs Fund (CDF), it was revealed today, just a day after the drug won conditional regulatory approval from the European Commission. 2 July 2019
Biotechnology
The precision medicine hypothesis that the genetics of a patient’s cancer will determine their response to a treatment has been thrown into doubt by new research by the UK’s Institute of Cancer Research (ICR). 1 July 2019
Biotechnology
Libtayo (cemiplimab) has been granted conditional approval for the treatment of certain adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), one of the most commonly diagnosed skin cancers worldwide. 1 July 2019
Biotechnology
Germany’s Boehringer Ingelheim today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of non-alcoholic steatohepatitis (NASH) and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. 1 July 2019
Biotechnology
Novartis has grabbed many of the recent headlines in the field of spinal muscular atrophy (SMA), a leading genetic cause of infant mortality. 1 July 2019
Biotechnology
Opthalmology specialist Ocular Therapeutix has launched its lead product in the USA for the treatment of ocular inflammation and pain following ophthalmic surgery. 1 July 2019
Biotechnology
Sun Pharmaceutical Industries has entered into a licensing agreement with a subsidiary of China Medical System Holdings (CMS) for the development and commercialization of tildrakizumab in Greater China. 1 July 2019
Biotechnology
Despite competition in the anti-CGRP migraine therapy space, Swiss pharma giant Novartis’ Aimovig (erenumab) has become the most-prescribed in the since its launch last year. 1 July 2019
Biotechnology
French nanomedicine company Nanobiotix today announced organizational changes to align with strategic priorities post European market approval for Hensify (NBTXR3), which was cleared for marketing in April. 1 July 2019
Biotechnology
There was good news for Zogenix after a meeting with the US Food and Drug Administration (FDA). 28 June 2019
Biotechnology
Privately-held Danish vaccines specialist AJ Vaccines has won approval in Denmark for its adjuvanted IPV vaccine, after positive results from clinical trials involving almost 3,000 infants. 28 June 2019
Biotechnology
Danish drugmaker Genmab has won US approval for Darzalex (daratumumab), in combination with lenalidomide and dexamethasone (Rd) to treat people with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). 28 June 2019
Biotechnology
In a historic decision, the US Food and Drug Administration approved Soliris (eculizumab) for a rare neurological disorder. 28 June 2019
Biotechnology
French CNS specialist Theranexus, which is developing drugs modulating the interaction between neurons and glial cells, has announced an agreement in principle with Beyond Batten Disease Foundation (BBDF). 28 June 2019
Biotechnology
New data for UK-based pharma giant AstraZeneca show the efficacy of its checkpoint inhibitor Imfinzi (durvalumab) in extensive-stage small cell lung cancer (SCLC). 28 June 2019
Biotechnology
OncoSec Medical has entered into a new collaboration with the Dana-Farber Cancer Institute to develop CAR T-cell therapies targeting solid tumors in patients with triple negative breast cancer, among other indications. 28 June 2019
Biotechnology
A new cholera vaccine, in Phase III trials, is expected to be six times cheaper than the three currently available in India, making it more cost-effective for inclusion in public health programs, reports The Pharma Letter’s local correspondent. 27 June 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze